Albert Schweitzer Ziekenhuis — Clinical Trial Site

125 Registered trials

53 Currently recruiting

Organisation

Albert Schweitzer Ziekenhuis

Location

Dordrecht, Netherlands

Identifier

ORG-100042264

Address

Langeweg 336, 3331 LZ, Netherlands

Departments

-
#2153: Hematology
#2201: oncology
#2906:Internal Medicine
031006: Oncology
5002:Internal medicine
Afd. Interne geneeskunde
Afdeling Interne geneeskunde, Trials & Research
Afdeling Interne geneeskunde
ASZ Dordrecht dept. Internal medicine
Cardiologie
Cardiology
Clinical Pharmacy
Department Internal Medicine
Department of Hematology
Department of Internal Medicine
Department of Surgical Oncology
Diabatescentrum voor volwassenen (Diabetes center for adults)
Endocrinologie
Gastroenterology
Gynaecology
Hematologie
Hematology
Intensive Care
Internal Medicine
Internal Medicine - Hematology
Internal medicine - oncology
Internal Medicine / Oncology
Internal Medicine Department
Internal Medicine, Hemato-Oncology
Internal medicine, hematology
Internal Medicine, Vascular Medicine
Internal medicine/haematology
Internal Oncology
Interne geneeskunde
Interne geneeskunder
Longziekten
Maag-, Darm- en Leverziekten
MDL
Medical Oncology
N/A
NA
Nefrologie
Nephrology
Neurology
NL10003: Internal medicine
Obstetrics & Gynecology
Oncologie
Oncology
Ophthalmology
Rheumatology
Surgery

Clinical trials at this site (125)

Search interface

VulVaccin study Recruiting

2023-506792-94-00 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSI 11 2024-03-04
A study to investigate the effect of adding cobicistat to venetoclax and azacitidine in patients with acute myeloid leukemia (AML) who are i… Recruiting

2023-505379-61-00 Acute Myeloid Leukaemia 4 2024-01-17
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Newly Diagnosed Multiple Myeloma (NDMM) 5 2023-09-29
MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex… Recruiting

2024-514139-50-00 Multiple myeloma 5 2022-11-14
Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting

2023-508389-13-00 Combined endpoint of all-cause mortality, kidney failur 5 2022-11-08
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia… Recruiting

2023-510384-36-00 Newly Diagnosed Multiple Myeloma 5 2022-09-13
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
Treatment of chronic lymphocytic leukaemia with venetoclax and acalabrutinib in case of return of the disease after previous treatment with … Recruiting

2023-505449-18-00 Patients with relapsed CLL 4 2020-07-23
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended

2024-518457-42-00 chronic kidney disease 4 2025-08-28
A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended

2024-518998-33-00 Ulcerative Colitis 5 2025-07-23
A Study of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease Ended

2024-517143-31-00 Autosomal Dominant Polycystic Kidney Disease 4 2025-07-18
A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended

2024-516511-24-00 Chronic myeloid leukaemia 11 2024-11-14
Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point… Ended

2024-511530-12-01 Rheumatoid arthritis according to 2010 criteria 6 2024-10-01
First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in… Ended

2022-502808-72-00 Chronic Lymphocytic Leukemia 4 2024-09-11
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended

2024-510965-41-00 Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymph 5 2024-09-03
MAD Ended

2024-516379-34-00 Myopia 6 2024-08-02
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended

2023-506457-38-00 Chronic kidney disease (CKD) and hypertension. 5 2024-06-05
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i… Ended

2023-506948-17-00 Previously Untreated Chronic Lymphocytic Leukemia 5 2024-04-05
A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati… Ended

2023-504124-26-00 Chronic Kidney Disease and High Proteinuria 5 2024-04-04